Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
NRAS exon 4
|
rectum cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 4 mutations (NCCN.org).
|
detail...
|
ERBB2 L866M
|
colorectal cancer
|
resistant |
Panitumumab
|
Preclinical |
Actionable |
In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
|
26243863
|
Unknown unknown
|
colorectal cancer
|
not applicable |
Panitumumab
|
FDA approved |
Actionable |
In an open-label clinical trial that supported FDA approval, Vectibix (panitumumab) treatment in patients with metastatic colorectal cancer resulted in increased progression-free survival (13.8 weeks; SD=0.76) compared to best supportive care alone (8.5 weeks; SD=0.54) (PMID: 18316547).
|
18316547
detail...
|
NRAS exon 3
|
rectum cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 3 mutations (NCCN.org).
|
detail...
|
Unknown unknown
|
Advanced Solid Tumor
|
not applicable |
Panitumumab
|
Phase I |
Actionable |
In a Phase I trial, Vectibix (panitumumab) demonstrated safety and anti-tumor activity in patients with advanced solid tumors (PMID: 18223225).
|
18223225
|
NRAS exon 3
|
colon cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org).
|
detail...
|
ERBB2 V842I
|
colorectal cancer
|
resistant |
Panitumumab
|
Preclinical |
Actionable |
In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
|
26243863
|
MAP2K1 K57T
|
colorectal cancer
|
resistant |
Panitumumab
|
Preclinical |
Actionable |
In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).
|
26644315
|
KRAS exon 4
|
colon cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 4 mutations (NCCN.org).
|
detail...
|
KRAS G12X
|
colorectal cancer
|
resistant |
Panitumumab
|
Phase III |
Actionable |
In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763).
|
18316791
|
MAP2K1 K57N
|
colorectal cancer
|
resistant |
Panitumumab
|
Preclinical |
Actionable |
In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).
|
26644315
|
NRAS exon 2
|
rectum cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 2 mutations (NCCN.org).
|
detail...
|
KRAS exon 4
|
rectum cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in rectum cancer patients with KRAS exon 4 mutations (NCCN.org).
|
detail...
|
NRAS wild-type
|
colorectal cancer
|
predicted - sensitive |
Panitumumab
|
Phase III |
Actionable |
In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).
|
26341920
|
ERBB2 L755S
|
colorectal cancer
|
resistant |
Panitumumab
|
Preclinical |
Actionable |
In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
|
26243863
|
KRAS exon 3
|
rectum cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in rectum cancer patients with KRAS exon 3 mutations (NCCN.org).
|
detail...
|
NRAS exon 2
|
colon cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org).
|
detail...
|
BRAF V600E
|
rectum cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in rectum cancer patients with BRAF V600E unless it is given with a BRAF inhibitor (NCCN.org).
|
detail...
|
ERBB2 S310F
|
colorectal cancer
|
resistant |
Panitumumab
|
Preclinical |
Actionable |
In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
|
26243863
|
KRAS exon 3
|
colon cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 3 mutations (NCCN.org).
|
detail...
|
BRAF V600E
|
colon cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).
|
detail...
|
KRAS wild-type
|
colorectal cancer
|
sensitive |
Panitumumab
|
Phase III |
Actionable |
In a post-hoc analysis of a Phase III trial, colorectal cancer patients with KRAS wild-type demonstrated a greater overall survival (8.1 mo) upon treatment with Vectibix (panitumumab) compared to overall survival (4.4 mo) of patients with KRAS mutations randomized to best supportive care only (PMID: 23625191; NCT00113763).
|
23625191
|
KRAS wild-type
|
colorectal cancer
|
sensitive |
Panitumumab
|
Phase III |
Actionable |
In a Phase III trial, Vectibix (panitumumab) treatment resulted in better overall survival (HR = 0.65) compared to Erbitux (cetuximab) in colorectal cancer patients harboring KRAS with wild-type exon 2 who received prior Avastin (bevacizumab) treatment (J Clin Oncol 34, 2016 (suppl; abstr 3538); NCT01001377).
|
detail...
|
KRAS wild-type
|
colorectal cancer
|
sensitive |
Panitumumab
|
FDA approved |
Actionable |
In a Phase III trial that supported FDA approval, Vectibix (panitumumab) demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS, resulting in a median progression-free survival of 12.3 weeks, compared to 7.3 weeks with best supportive care (BSC), improved overall survival (HR=0.67), and a response rate of 17% (21/141) (PMID: 18316791; NCT00113763).
|
18316791
|
HRAS G12V
|
Advanced Solid Tumor
|
resistant |
Panitumumab
|
Preclinical |
Actionable |
In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Vectibix (panitumumab) (PMID: 22797062).
|
22797062
|
Unknown unknown
|
gastric adenocarcinoma
|
no benefit |
Panitumumab
|
Phase III |
Actionable |
In a Phase III trial, addition of Vectibix (panitumumab) to chemotherapy consisted of epirubicin, oxaliplatin, and capecitabine (EOC) did not improve overall survival and increased side effects, therefore was not recommended in an unselected population of patients with advanced oesophagogastric adenocarcinoma (PMID: 23594787).
|
23594787
|
MET over exp
|
colorectal cancer
|
resistant |
Panitumumab
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, over expression of MET conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478).
|
23729478
|
NRAS exon 4
|
colon cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org).
|
detail...
|
KRAS G13X
|
colorectal cancer
|
resistant |
Panitumumab
|
Phase III |
Actionable |
In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763).
|
18316791
|
ERBB2 V777L
|
colorectal cancer
|
resistant |
Panitumumab
|
Preclinical |
Actionable |
In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
|
26243863
|
KRAS exon 2
|
colon cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 2 mutations (NCCN.org).
|
detail...
|
KRAS exon 2
|
rectum cancer
|
resistant |
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in rectum cancer patients with KRAS exon 2 mutations (NCCN.org).
|
detail...
|